TSO3 re-evaluates protocol for
the current phase of testing on prions
TSX Stock Symbol: TOS
Outstanding Shares: 31,400,295
QUEBEC CITY, Aug. 12 /CNW Telbec/ - Before
the planned end of the third phase of testing on prions underway
at the National Research Council of Canada
(NRC) facilities in Winnipeg, TSO3 has not obtained the results
The partial deactivation of prions has generated symptoms of the
disease in certain subjects inoculated with substances extracted
from plaques sterilized with ozone. This partial deactivation is
not concordant with the results obtained in previous studies where
ozone showed a capacity to deactivate prions superior to the level
observed during the current phase of testing.
"These partial results are disappointing, however the recognized
oxidizing power of ozone, as well as the results of our previous
studies, moves us to re-evaluate our current protocols and to maintain
our research program. We still believe in the superior capacity
of ozone to deactivate prions," emphasized Simon Robitaille, Vice
President, Operations, and Director of Research at TSO3.
After the start of this third phase of TSO3's program and again
only recently, new scientific publications utilizing a different
methodology impelled TSO3 to re-evaluate the Company's protocols
so that its results can be compared to those obtained through the
other sterilization technologies.
The measuring technique for residual infectious capability utilized
in the recent studies in question has the advantage of corresponding
more closely to the usual practice in hospitals.
The current testing consists of taking the brains from sick mice
and making a homogenate that is spread on plaques and left to dry,
then sterilized in the ozone sterilizer, while other samples are
sterilized with steam, in order to compare the effectiveness of
ozone to the autoclave. The residual matter is then recovered and
injected into the brains of mice. This phase was planned to take
six months, scheduled to conclude at the end of October 2004.
TSO3 intends to initiate a new phase of testing, with new protocols,
at the end of 2004.
"As far as our commercialization strategy is concerned, the business
plan for the 125L Ozone Sterilizer is based on the benefits of our
technology, such as its efficiency, its rapidity and cost advantages.
This news in no wise affects TSO3's business plan. Nor will it impact
the commercial launch of the 125L or its expected market penetration,"
added Jocelyn Vézina, the Chief Executive Officer at TSO3.
TSO3 Inc. is located in Québec City, Québec, Canada, and was founded
in 1998. TSO3 currently has 45 employees, 17 of whom work exclusively
in the Research and Development department. The company's mission
is to develop and market innovative and comprehensive sterilization
TSO3 has perfected a novel sterilization process using ozone as
a sterilizing agent. The first product based on this technological
platform is the 125L Ozone Sterilizer, which is intended for hospital
sterilization units. The 125L - named after its 125-litre/4.3-cubic-foot
capacity - was designed to sterilize the new generation of surgical
and diagnostic instruments made of non-heat-resistant materials
such as polymers and other plastics. The ozone sterilization process
is a safe, efficient, fast and cost-effective response to evolving
The 125L Ozone Sterilizer by TSO3 was cleared for commercialization
by Health Canada in May 2002 and the U.S. Food and Drug Administration
(FDA) on September 3, 2003.
The Company's R&D team has also undertaken the development of a
smaller, point-of-use ozone sterilization device for operating rooms
and private clinics, and is planning the development of an industrial-sized
manufacturers of medical instruments, among others.
For more information on TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by representatives
of TSO3 relating to matters that are not historical facts(including,
without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3,are forward-looking statements that
involve certain risks, uncertainties and hypotheses, including,
but not limited to, general business and economic conditions, the
condition of the financial markets, the ability of TSO3 to obtain
financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.